Table 2. Some examples of correct interactions predicted for the 50 most frequently sold drugs in 2010 in which the model generated interactions through the comparison of drugs belonging to different pharmacological classes.
| Similar drug to A1 | Predicted interaction DrugA-DrugB | Similar drug to B1 | TC | Predicted effect |
| Aripiprazole-Nelfinavir | Itraconazole | 0.55 | Increased effect of aripiprazole | |
| Aripiprazole-Atazanavir | Ketoconazole | 0.45 | Increased effect of aripiprazole | |
| Alprazolam | Atorvastatin-Digoxin | 0.40 | Increased effect of digoxin | |
| Midazolam | Atorvastatin-Omeprazole | 0.51 | Increased effect of atorvastatin | |
| Atorvastatin-Miconazole | Imatinib | 0.43 | Increased effect and toxicity of atorvastatin | |
| Buprenorphine-Trospium | Triprolidine | 0.43 | Possible increase adverse/toxic effects due to additivity | |
| Buprenorphine-Trimethobenzamide | Triprolidine | 0.40 | Possible increase adverse/toxic effects due to additivity | |
| Felodipine | Conjugated_Estrogens-Oxcarbazepine | 0.51 | Decreased levels of estrogens | |
| Gefitinib | Conjugated_Estrogens-Clarithromycin | 0.47 | Increased levels/toxicity of estrogens | |
| Nifedipine | Conjugated_Estrogens-Cimetidine | 0.40 | Increased the effect of estrogens | |
| Duloxetine-Tolterodine | Tamsulosin | 0.59 | Possible decreased metabolism and clearance of Tolterodine. Changes in therapeutic/adverse effects of Tolterodine | |
| Duloxetine-Trimethobenzamide | Triprolidine | 0.40 | Possible increase adverse/toxic effects due to additivity | |
| Duloxetine-Sibutramine | Zolmitriptan | 0.53 | Increased risk of serotonin syndrome | |
| Escitalopram-Amoxapine | Linezolid | 0.40 | Possible serotoninergic syndrome | |
| Eszopiclone-Trimethobenzamide | Triprolidine | 0.40 | Possible increased adverse/toxic effects due to additivity | |
| Ethinyl_Estradiol-Trimipramine | Tacrolimus | 0.43 | Possible increased blood concentration of Trimipramine | |
| Cisapride | Levofloxacin-Propafenone | 0.44 | Increased risk of cardiotoxicity and arrhytmias | |
| Methylphenidate-Linezolid | Rasagiline | 0.52 | Possible hypertensive crisis with this combination | |
| Gefitinib | Norethindrone-Voriconazole | 0.48 | Possible increased serum concentration of norethindrone. Changes in the therapeutic and adverse effects | |
| Oxycodone-Trospium | Triprolidine | 0.43 | Possible increased adverse/toxic effects due to additivity | |
| Pioglitazone-Nelfinavir | Ketoconazole | 0.51 | Increased the effect of pioglitazone | |
| Dihydroergotoxine | Salmeterol-Delavirdine | 0.48 | Increase salmeterol toxicity | |
| Lidocaine | Salmeterol-Atazanavir | 0.56 | Increased risk of cardiotoxicity and arrhythmias | |
| Sildenafil-Clonidine | Terazosin | 0.47 | Increased risk of hypotension | |
| Simvastatin-Conivaptan | Imatinib | 0.43 | Increased effect and toxicity of statin | |
| Bromazepam | Tadalafil-Rifabutin | 0.50 | Possible decreased serum concentration of Tadalafil. Changes in the therapeutic and adverse effects | |
| Tadalafil | Zolpidem-Doxazosin | 0.55 | Risk of significant hypotension with this association |
TC is the Tanimoto coefficient.
1
The similarity between drugs is based on the drug-drug interaction profile.